| Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference H Northrup, DA Krueger, S Roberds, K Smith, J Sampson, B Korf, ... Pediatric neurology 49 (4), 243-254, 2013 | 1661 | 2013 |
| Angiotensin II type 1–receptor activating antibodies in renal-allograft rejection D Dragun, DN Müller, JH Bräsen, L Fritsche, M Nieminen-Kelhä, ... New England Journal of Medicine 352 (6), 558-569, 2005 | 1020 | 2005 |
| Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo … JJ Bissler, JC Kingswood, E Radzikowska, BA Zonnenberg, M Frost, ... The Lancet 381 (9869), 817-824, 2013 | 970 | 2013 |
| Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference DA Krueger, H Northrup, S Roberds, K Smith, J Sampson, B Korf, ... Pediatric neurology 49 (4), 255-265, 2013 | 923 | 2013 |
| Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus F Vincenti, S Friman, E Scheuermann, L Rostaing, T Jenssen, ... American Journal of Transplantation 7 (6), 1506-1514, 2007 | 749 | 2007 |
| Everolimus in patients with autosomal dominant polycystic kidney disease G Walz, K Budde, M Mannaa, J Nürnberger, C Wanner, C Sommerer, ... New England Journal of Medicine 363 (9), 830-840, 2010 | 727 | 2010 |
| Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report M Brunet, T Van Gelder, A Åsberg, V Haufroid, DA Hesselink, L Langman, ... Therapeutic drug monitoring 41 (3), 261-307, 2019 | 582 | 2019 |
| Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ... The Lancet 393 (10184), 1937-1947, 2019 | 543 | 2019 |
| Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations H Northrup, ME Aronow, EM Bebin, J Bissler, TN Darling, PJ de Vries, ... Pediatric Neurology 123, 50-66, 2021 | 435 | 2021 |
| Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts N Lachmann, PI Terasaki, K Budde, L Liefeldt, A Kahl, P Reinke, ... Transplantation 87 (10), 1505-1513, 2009 | 432 | 2009 |
| Biomarkers in acute kidney injury–pathophysiological basis and clinical performance EV Schrezenmeier, J Barasch, K Budde, T Westhoff, KM Schmidt‐Ott Acta physiologica 219 (3), 556-574, 2017 | 431 | 2017 |
| Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial K Budde, T Becker, W Arns, C Sommerer, P Reinke, U Eisenberger, ... The Lancet 377 (9768), 837-847, 2011 | 429 | 2011 |
| CC chemokine receptor 5 and renal-transplant survival M Fischereder, B Luckow, B Hocher, RP Wüthrich, U Rothenpieler, ... The Lancet 357 (9270), 1758-1761, 2001 | 388 | 2001 |
| Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions A Sharif, M Hecking, APJ De Vries, E Porrini, M Hornum, ... American Journal of Transplantation 14 (9), 1992-2000, 2014 | 371 | 2014 |
| Neutrophil gelatinase‐associated lipocalin: pathophysiology and clinical applications E Singer, L Markó, N Paragas, J Barasch, D Dragun, DN Müller, K Budde, ... Acta physiologica 207 (4), 663-672, 2013 | 367 | 2013 |
| First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients K Budde, RL Schmouder, R Brunkhorst, B Nashan, PW Lu, T Mayer, ... Journal of the American Society of Nephrology 13 (4), 1073-1083, 2002 | 356 | 2002 |
| Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial T van Gelder, HT Silva, JW de Fijter, K Budde, D Kuypers, G Tyden, ... Transplantation 86 (8), 1043-1051, 2008 | 339 | 2008 |
| Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction F Diekmann, K Budde, F Oppenheimer, L Fritsche, HH Neumayer, ... Transplantation 78 (2), 115, 2004 | 314 | 2004 |
| Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study K Budde, J Curtis, G Knoll, L Chan, HH Neumayer, Y Seifu, M Hall, ... American Journal of Transplantation 4 (2), 237-243, 2004 | 313 | 2004 |
| Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation L Rostaing, D Cantarovich, G Mourad, K Budde, P Rigotti, C Mariat, ... Transplantation 79 (7), 807-814, 2005 | 308 | 2005 |
Roland RollerGerman Research Center for Artificial Intelligence (DFKI)Verified email at dfki.de